STAT reporter Casey Ross writes about how MIT researchers have developed a new ingestible Prof. Timothy Lu explains that he hopes that the sensor “opens up a really new window into how the gut and the rest of the body are connected, and hopefully provide new diagnostic strategies as well.”
New York Times reporter Steve Lohr writes about the MIT AI Policy Conference, which examined how society, industry and governments should manage the policy questions surrounding the evolution of AI technologies. “If you want people to trust this stuff, government has to play a role,” says CSAIL principal research scientist Daniel Weitzner.
Guardian reporter Ian Sample writes that MIT startup Synlogic are developing a “living” medicine” made from genetically modified bugs. “By engineering these bacteria, we are able to control how they operate in the human gastrointestinal tract,” says Caroline Kurtz of Synlogic. “It allows us to think about many other diseases where you may need to produce something beneficial, or remove something that is toxic for the patient.”
MIT researchers have developed an inhalable form of messenger RNA that could be used to help treat patients with lung disease, reports Christopher Intagliata for Scientific American. Intagliata explains that researchers hope to one day “use this technique to help cystic fibrosis patients.”
CBS Boston reporter Dr. Mallika Marshall spotlights research by researchers at MIT and Brigham and Women’s Hospital to develop robotic prosthetic limbs controlled by the brain. “It’s a wonderful experience as a researcher,” explains Herr of the work’s impact. “They walk away and start crying or laughing and giggling and say, ‘my gosh I have my body back, I have leg back, I have my life back.’”
MIT researchers have developed a remote-controlled ingestible capsule that can be operated by a user’s smartphone, reports the Xinhua news agency. “The researchers envisioned that this type of sensor could be used to diagnose early signs of disease and then respond with the appropriate medication,” Xinhua explains.
HealthDay News reporter E.J. Mundell writes that MIT researchers have developed an ingestible capsule that can be used to monitor health a patient’s health. “The capsule could deliver drugs as well as sense the condition of its surroundings in the gut, including infections or allergic reactions,” Mundell explains.
MIT researchers have engineered wasp venom to kill bacteria, reports Chukwuma Muanya for The Guardian. The researchers found that the altered peptides wiped out the antibiotic-resistant bacteria Pseudomonas aeruginosa within four days.
Boston Globe reporter Jessie Scanlon spotlights Prof. Regina Barzilay’s work developing machine learning systems that can identify patients at risk of developing breast cancer. Barzilay is creating “software that aims to teach a computer to analyze mammogram images more effectively than the human eye can and to catch signs of cancer in its earliest phases.”
Forbes reporter Fiona McMillan writes that MIT researchers have engineered an anti-bacterial peptide found in wasp venom in an effort to create a new antibiotic. McMillan writes that the researchers, “gained new insight into which structural attributes work best, either alone or in combination. In this way, they were able to tweak the peptide’s structure to obtain optimal function.”
MIT researchers have repurposed the toxic venom found in wasps to create a new drug that could potentially be used to kill bacteria, reports the Xinhua news agency. “The venom-derived peptide is believed to kill microbes by disrupting bacterial cell membranes,” Xinhua explains.
Boston Herald reporter Jordan Graham writes that MIT researchers have used the venom from a South American wasp to engineer a new type of antibiotic. “The idea here is to take that very well-crafted toxin and turn it into something that can be useful for humans and our society,” explains César de la Fuente Nunez, a postdoc at MIT.
Prof. Linda Griffith speaks with Hari Sreenivasan of PBS NewsHour about her work developing a new “body on a chip” that could allow researchers to test new drugs on organ tissue. Griffith explains that the device models how different organs and cells communicate in the human body, which is “really important for things like arthritis, Alzheimer's, where you've got multiple organs involved.”
MIT startup Lyndra has found that an ingestible device originally developed by researchers from MIT and Brigham and Women’s Hospital can help tackle the problem of medication adherence, reports Kate Sheridan for STAT. The new technology could make it possible for patients to take “one pill a week for conditions as varied as Alzheimer’s, addiction, allergies, malaria, schizophrenia, high cholesterol, and HIV.”
Prof. Linda Griffith speaks with Wall Street Journal reporter Mark Ellwood about her work developing a new device that allows researchers to test how a drug affects the human body. Ellwood notes that the technology that Griffith and her team have created “could prove vital for rapidly releasing new vaccines.”